GSK 4716
Modify Date: 2024-01-05 18:17:49
GSK 4716 structure
|
Common Name | GSK 4716 | ||
|---|---|---|---|---|
| CAS Number | 101574-65-6 | Molecular Weight | 282.33700 | |
| Density | 1.12g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C17H18N2O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07, GHS09 |
Signal Word | Warning | |
Use of GSK 4716GSK-4716 is a selective ERRβ/γ agonist. |
| Name | 4-hydroxy-N-[(E)-(4-propan-2-ylphenyl)methylideneamino]benzamide |
|---|---|
| Synonym | More Synonyms |
| Description | GSK-4716 is a selective ERRβ/γ agonist. |
|---|---|
| Related Catalog | |
| Target |
ERRβ/γ[1] |
| In Vitro | Treatment of differentiated C2C12 cells with the ERRβ/γ agonist (relative to vehicle) over a 2 to 4 h time period reveals a reproducible and robust increase in the immunoreactivity of the GRα-D isoform. It is observed that MAO-A mRNA expression is significantly increased by treatment with the ERRβ/γ agonist, GSK4716. Furthermore, it is observed that GSK4716 induces the expression of the mRNAs encoding peroxisome proliferator-activated receptor-γcoactivator 1α (PGC-1α) and PGC-1β (key regulator of many metabolic genes) identified as direct coactivators for the ERR family. GSK4716 induces the expression of PGC-1 and genes involved in fatty acid oxidation in concordance with the characterized role of ERRγ in cardiac metabolism[1]. Treatment of primary mouse myotubes with GSK4716, an ERRβ/γ agonist, results in a concerted increase in the expression levels of Ppargc1a, Ppargc1b, and the Esrr genes. Furthermore,Cpt1b, Atp5b, and Idh3, genes in key mitochondrial pathways, are also induced by GSK4716. Additionally, GSK4716 increases citrate synthase activity and cytochrome c protein levels[2]. |
| Cell Assay | Proliferating mouse C2C12 myoblast are cultured and maintained in DMEM supplemented with 10% heat-inactivated serum supreme. Differentiation of myoblasts into post-mitotic, multi-nucleated myotubes are induced by mitogen withdrawal (DMEM supplemented with 2% horse serum) for 4 days. C2C12 myotubes are treated with either vehicle (DMSO) or ERRβ/γ agonist GSK4716 for 1 day and RNA collected and processed[1]. |
| References |
| Density | 1.12g/cm3 |
|---|---|
| Molecular Formula | C17H18N2O2 |
| Molecular Weight | 282.33700 |
| Exact Mass | 282.13700 |
| PSA | 61.69000 |
| LogP | 3.67040 |
| Index of Refraction | 1.576 |
| Storage condition | 2-8℃ |
| Symbol |
GHS07, GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H317-H410 |
| Precautionary Statements | P273-P280-P501 |
| RIDADR | UN 3077 9 / PGIII |
| GSK 4716 |
| 2gpp |
| QCR-163 |
| GSK-4716 |